Related Articles
Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor‑resistant gastroesophageal reflux disease
Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors
Efficacy of a potassium‑competitive acid blocker for improving symptoms in patients with reflux esophagitis, non‑erosive reflux disease, and functional dyspepsia
Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease
Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users